Targeted design, synthesis, molecular simulation, ADME-T and in-vitro anticancer assessment of phenyl-substituted-thioxo-tetrahydro-pyrimidin-benzenesulfonamide derivatives as potential BRAFV600E/WT inhibitors.

Abstract excerpt

BRAF is one of the most commonly mutated oncogenes in human cancers, with more than 90 % of mutations occurring at codon 600. Among these, BRAFV600E is the most prevalent, accounting for nearly 90 % of all BRAF codon 600 mutations, while the less frequent variants are collectively referred to as BRAFV600WT. BRAF mutations are reported across several cancers, with the highest frequency in malignant melanoma...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Design
• Share to Drug Screening Assays, Antitumor